TY - JOUR
T1 - Progressively decreasing plasma high-density lipoprotein cholesterol levels preceding diagnosis of smoldering myeloma
AU - Tavori, Hagai
AU - Ormseth, Michelle J.
AU - Lilley, Jessica S.
AU - Papen, Courtney R.
AU - May-Zhang, Linda S.
AU - Davies, Sean S.
AU - Linton, MacRae F.
AU - Fazio, Sergio
N1 - Funding Information:
This work is dedicated to the late Dr Fred Faas, who was chair of the Division of Endocrinology and Metabolism at the University of Arkansas when these studies were performed. The authors would like to acknowledge Drs Jonathan Stinger and Monica Agarwal, formerly in the Division of Endocrinology and Metabolism at the University of Arkansas, for the excellent care provided for this patient. This study was supported by the American Heart Association grant 16SDG27520011 to HT and by Veterans Health Administration grant CDA IK2CX001269 to MJO.
Publisher Copyright:
© 2020 National Lipid Association
PY - 2020/5/1
Y1 - 2020/5/1
N2 - We report a case of disappearing high-density lipoprotein (HDL) syndrome caused by oxidative modification of HDL and by autoantibodies against modified HDL, with subsequent diagnosis of myeloma. An elderly Caucasian man had normal lipid levels with HDL cholesterol (HDL-C) levels in the upper 70 mg/dL range from 1999 to 2003. In 2003, his HDL-C levels began to progressively fall, and by 2011, they were undetectable (<5 mg/dL) when measured with a Beckman Synchron LX auto analyzer. Analyses of the plasma sample from 2011 using ultracentrifugation (Vertical Auto Profile), nuclear magnetic resonance, and Ace EXCEL auto analyzer have shown that HDL-C levels were easily detectable (47–54 mg/dL), although reduced compared with his pre-2003 values. Analyses of his plasma sample from 2011 also showed the presence of lipid-adducted apolipoprotein A1 (apoA1) and high titer of antibodies against the adducted apoA1. Interestingly, a negative correlation between HDL-C levels and the titer of antibodies against apoA1 adducts was found in the control cohort. Finally, we show that in the mouse system, an antibody against apoA1 increases the clearance of HDL from plasma. This case of smoldering myeloma preceded by acquired, severe HDL-C deficiency, likely because of oxidative modifications of the HDL protein leading to the formation of autoantibodies, interference with clinical measurement of HDL-C, and increased plasma clearance of HDL, adds to the list of diagnostic considerations for unexplained HDL-C decreases over time.
AB - We report a case of disappearing high-density lipoprotein (HDL) syndrome caused by oxidative modification of HDL and by autoantibodies against modified HDL, with subsequent diagnosis of myeloma. An elderly Caucasian man had normal lipid levels with HDL cholesterol (HDL-C) levels in the upper 70 mg/dL range from 1999 to 2003. In 2003, his HDL-C levels began to progressively fall, and by 2011, they were undetectable (<5 mg/dL) when measured with a Beckman Synchron LX auto analyzer. Analyses of the plasma sample from 2011 using ultracentrifugation (Vertical Auto Profile), nuclear magnetic resonance, and Ace EXCEL auto analyzer have shown that HDL-C levels were easily detectable (47–54 mg/dL), although reduced compared with his pre-2003 values. Analyses of his plasma sample from 2011 also showed the presence of lipid-adducted apolipoprotein A1 (apoA1) and high titer of antibodies against the adducted apoA1. Interestingly, a negative correlation between HDL-C levels and the titer of antibodies against apoA1 adducts was found in the control cohort. Finally, we show that in the mouse system, an antibody against apoA1 increases the clearance of HDL from plasma. This case of smoldering myeloma preceded by acquired, severe HDL-C deficiency, likely because of oxidative modifications of the HDL protein leading to the formation of autoantibodies, interference with clinical measurement of HDL-C, and increased plasma clearance of HDL, adds to the list of diagnostic considerations for unexplained HDL-C decreases over time.
KW - Autoantibodies
KW - Disappearing HDL
KW - Dyslipidemia
KW - Isolevuglandin adducts
UR - http://www.scopus.com/inward/record.url?scp=85084127605&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084127605&partnerID=8YFLogxK
U2 - 10.1016/j.jacl.2020.04.001
DO - 10.1016/j.jacl.2020.04.001
M3 - Article
C2 - 32376310
AN - SCOPUS:85084127605
SN - 1933-2874
VL - 14
SP - 293
EP - 296
JO - Journal of clinical lipidology
JF - Journal of clinical lipidology
IS - 3
ER -